THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms

Ann Transl Med. 2014 Jan;2(1):1. doi: 10.3978/j.issn.2305-5839.2013.07.03.

Abstract

Targeted, personalized or molecular medicine all imply maximal treatment with minimal side effects and requires definition and detection of molecular targets prior to therapy. THERANOSTICS in nuclear medicine utilizes the same vector with distinct radionuclides for diagnosis and treatment and has become innovative standard for the treatment of somatostatin receptor expressing neuroendocrine neoplasms.

Keywords: Molecular medicine; neuroendocrine neoplasms; peptide receptor radionuclide therapy; personalized medicine.